Recombinant human interferon gamma adenovirus injection (Guangzhou Dabo Biological Products)

重组人γ-干扰素腺病毒（达博生物）

Report date: 2023/10/26 16:21:39

Base Information

Drug NameRecombinant human interferon gamma adenovirus injection (Guangzhou Dabo Biological Products)
Drug Alias NameE10BAd/hIFN-γ
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionInterferon gamma stimulants
TargetsInterferon gamma
Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantNasopharyngeal NeoplasmsLiver Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGuangzhou Dabo Biological Products Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuangzhou Dabo Biological Products Co Ltd
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-Resistant
Inactive IndicationsNasopharyngeal NeoplasmsLiver Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A